IHE iShares U.S. Pharmaceuticals ETF Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
15:56
Feb 25
Feb 25
Schneider states a goal to "work on reducing the cost of medicines." This is standard Democratic policy rhetoric signaling continued legislative pressure on pharmaceutical pricing power. While the IRA (Inflation Reduction Act) already initiated this, continued focus suggests potential expansion of drug price negotiation lists. WATCH. Regulatory headwinds remain persistent for pure-play pharma. Gridlock in Congress preventing new legislation (bullish for Pharma).
12:11
Jan 23
Jan 23
Pharma headwinds lift small biotech M&A.
Large-cap pharmaceuticals face drug-price pressure, major patent expirations, and reduced internal R&D, so they will need to acquire innovation. That creates takeover tailwinds for small-cap biotech; because individual biotech names are volatile, he recommends a diversified portfolio of 20-30 names with higher likelihood of being acquired.
HIGH
About IHE Investor Commentary
Across the available history and selected sources, Buzzberg tracks IHE (iShares U.S. Pharmaceuticals ETF) across 2 sources: 0 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 0% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: Brad Schneider, Kevin Mahn.